Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun;40(2):589-601.
doi: 10.1007/s10555-021-09962-6. Epub 2021 Apr 14.

Exosomes: a new perspective in EGFR-mutated lung cancer

Amina Jouida  1 , Cormac McCarthy  1   2 , Aurelie Fabre  1   2 , Michael P Keane  3   4
Affiliations
Review

Exosomes: a new perspective in EGFR-mutated lung cancer

Amina Jouida et al. Cancer Metastasis Rev. 2021 Jun.

Abstract

Exosomes are major contributors in cell to cell communication due to their ability to transfer biological material such as protein, RNA, DNA, and miRNA. Additionally, they play a role in tumor initiation, promotion, and progression, and recently, they have emerged as a potential source of information on tumor detection and may be useful as diagnostic, prognostic, and predictive tools. This review focuses on exosomes from lung cancer with a focus on EGFR mutations. Here, we outline the role of exosomes and their functional effect in carcinogenesis, tumor progression, and metastasis. Finally, we discuss the possibility of exosomes as novel biomarkers in early detection, diagnosis, assessment of prognosis, and prediction of therapeutic response in EGFR-mutated lung cancer.

Keywords: Biomarker; EGFR; Exosome; Lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Exosomes display different functional roles a allowing potential use in the clinical application b in EGFR-mutated cancer
See this image and copyright information in PMC

References

    1. Tsao M-S, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, et al. Subtype classification of lung adenocarcinoma predicts benefit from adjuvant chemotherapy in patients undergoing complete resection. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2015;33(30):3439–3446. doi: 10.1200/JCO.2014.58.8335. - DOI - PMC - PubMed
    1. Tfayli AH, Fakhri GB, Al Assaad MS. Prevalence of the epidermal growth factor receptor mutations in lung adenocarcinoma patients from the Middle East region. Annals of Thoracic Medicine. 2019;14(3):173–178. doi: 10.4103/atm.ATM_344_18. - DOI - PMC - PubMed
    1. Zhang H. Osimertinib making a breakthrough in lung cancer targeted therapy. OncoTargets and therapy. 2016;9:5489–5493. doi: 10.2147/OTT.S114722. - DOI - PMC - PubMed
    1. Bernabé R, Hickson N, Wallace A, Blackhall FH. What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer? European Journal of Cancer (Oxford, England: 1990) 2017;81:66–73. doi: 10.1016/j.ejca.2017.04.022. - DOI - PubMed
    1. Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, et al. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer. Expert Review of Molecular Diagnostics. 2018;18(1):35–45. doi: 10.1080/14737159.2018.1407243. - DOI - PubMed